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Abstract: Fragile X–associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative
disorder that usually begins in the early 60s and affects carriers of premutation expansion
(55–200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. Additional
disorders can co-occur with FXTAS including Alzheimer’s disease (AD). Here we discuss
a case report of a male with 67 CGG repeats in FMR1 who had mild late-onset FXTAS
symptoms followed by neurocognitive disorder symptoms consistent with AD. The patient
has developed tremor and ataxia that are the two characteristic symptoms of FXTAS. In
addition, he shows rapid cognitive decline, brain atrophy most substantial in the medial
temporal lobe, and decreased metabolism in the brain regions that are the characteristic
findings of AD. The purpose of this study is to describe a patient profile with both diseases
and review the details of an overlap between these two diseases.
Keywords: FXTAS, Alzheimer’s disease, cognitive decline, neurocognitive disorder,
premutation, neurogenetics
Introduction
Fragile X–associated tremor/ataxia syndrome (FXTAS) is a late onset condition in
carriers of the premutation in the fragile X mental retardation 1 (FMR1) gene that
affects 40% of males and 16% of females.1 The most common features of FXTAS
are intention tremor, ataxia, memory and executive function deficits, autonomic
dysfunction, and brain atrophy with white matter disease.2 Patients with early
FXTAS usually present with autonomic dysfunction such as erectile dysfunction
and orthostatic hypotension. Cognitive decline can rarely be the first sign of FXTAS
while usually an intention tremor is the first sign.3,4
There are different types of molecular dysfunction that play a role in the
pathophysiology of FXTAS, although RNA toxicity caused by elevated levels of
the FMR1-mRNA is the most salient. The elevated mRNA can sequester proteins
important for neuronal function and form intranuclear inclusions in neurons and
astrocytes throughout the brain and in the peripheral nervous system.5,6 In addition,
mitochondrial deficits,7 calcium dysregulation,8 iron sequestration,9,10 chronic
DNA damage repair,2 microbleeds and the production of a toxic peptide
FMRpolyG due to RAN translation11 can occur in the brain. These processes can
lead to enhanced cell death of neurons and astrocytes leading to brain atrophy and
white matter disease in those with FXTAS.
There are different neurodegenerative disorders which can co-occur with
FXTAS including Alzheimer’s disease (AD),12,13 Parkinson’s Disease14 and
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multiple sclerosis.15 AD is also characterized by cognitive
deficits including encoding and recall of new information,
agnosia and impaired reasoning, judgement and problem
solving.16 The most important difference between FXTAS
neurocognitive disorder and AD neurocognitive disorder is
that the language performance is lower in AD than
FXTAS. On the other hand, executive functions are
lower in FXTAS than AD.12 There are several factors
that affect the progression of both diseases. The ApoE4
allele is one of the strongest genetic risk factors that
predisposes to AD. Although this patient does not have
the ApoE4 allele, he has a rapidly progressing neurocog-
nitive disorder which can be suggestive of an overlap
between FXTAS and AD.
In this paper, we describe a patient with the premuta-
tion and FXTAS who has had a significant progressive
cognitive decline over the last 4 years. He developed
tremor and ataxia which are characteristic of FXTAS. He
also demonstrated rapidly declining IQ and memory test-
ing scores during his follow-up over 10 years. These
findings in addition to the neuroimaging showing brain
atrophy, white matter disease, and decreased brain meta-
bolism are consistent with a diagnosis of both FXTAS
and AD. The purpose of this case study is to demonstrate
a profile of a patient with both conditions. We investigated
a possible exacerbation in the progression of these two
neurodegenerative diseases when there is an overlap
between these two disorders.
Methods
Patient has signed a written informed consent for imaging,
molecular testing, cognitive testing and publication
approved by the institutional IRB. The segmentation of
brain structures on the MRI scans was performed automa-
tically using Brain GPS27 followed by machine learning-
based error correction28 and manual editing.
Clinical Presentation
This case is an 84 year old male carrier of a FMR1
premutation allele of 67 CGG repeats with approximately
2-fold higher FMR1 mRNA expression levels. He was
first suspected to develop FXTAS about 10 years ago. His
initial symptoms were a mild intention tremor which
began intermittently at age 74 and ataxia that began at
age 75. His tremor started after his prostatectomy surgery
for prostate cancer that involved inhalant anesthesia. He
also noticed mild imbalance with his walking but he
denied other symptoms of ataxia. His tremor and ataxia
worsened after he developed chronic urinary tract infec-
tions. Since that time, he also had a mild but progressive
renal failure. At age 76, he started to feel numbness in
both feet and right thigh. At age 77, he was diagnosed
with severe anemia due to chronic kidney disease, in
addition to mitral valve prolapse. He was treated with
epoetin alfa, oral iron, and iron injections and his hema-
tocrit increased but his tremor worsened. He began to
experience inflammation in his joints particularly his fin-
gers. He was also diagnosed with sleep apnea at age 77
and he started to use a continuous positive airway pres-
sure (CPAP) machine. He tore his right shoulder rotator
cuff and he was treated with cortisone injections. He
reported that his ongoing stiffness was improved with
this treatment.
At age 78, his tremor improved with propranolol treat-
ment. At the age of 79, he reported a decrease in overall
stamina and started to nap about 4 times a day. His sense
of hearing started to decrease on his left side. His anemia
became worse and he started to take iron supplements
again. Low energy and fatigue were his primary concerns.
At age 82 he reported that he had symptoms of lighthead-
edness on a regular basis and he had memory problems but
he was in the normal range in the cognitive testing (see
Table 1). After a year, he started to undergo significant
cognitive changes particularly in both long term and short
term memory. He had problems with remembering his
routines at his temple and with his family. His executive
function abilities started to diminish (Table 1). His daugh-
ters reported that he was more withdrawn, less verbal, less
interactive and less interested in the activities that were
going on around him. He also started to overexpress his
emotions. He had problems with insomnia for several
years even with the CPAP. Currently, he is 84 years old
and he has a significant cognitive decline which acceler-
ated 2 years ago. He continues to have problems in word
retrieval and focusing his attention. He hardly initiates
conversations and he sleeps more during the day. He,
however, continues to work out regularly which is
a routine that began even before the onset of FXTAS.
His wife reports that he sometimes sits on the couch
spending hours looking at the wall and playing with his
dog. He has high blood pressure which is commonly seen
in premutation carriers particularly with FXTAS. He also
has an affectionate behavior to all people around him
related to his increasing frontal disinhibition. His ataxia
was helped by balance therapy administered by his PT. He
has a history of major depressive disorder at age 52 which
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was treated by escitalopram oxalate 20 mg and cognitive
behavioral therapy.
The family history is significant for the death of his
brother from FXTAS in 2016, his daughters are carriers of
the FMR1 premutation, and he has a grandson with a full
mutation causing fragile X syndrome. The patient reported
experiencing the death of his brother as a major life
stressor.
In 2018, on his examination, his blood pressure was
150/80. His weight was 73.9 kg and height was 177.8 cm.
His hearth rate was 80. On his eye examination, he had
normal eye movements but he had pinpoint pupils that
were minimally reactive to light and he had a gray ring
at his corneal margin. He had a mildly hypoactive gag and
his cranial nerves showed decreased hearing bilaterally at
approximately 20% of normal. He had a bifid uvula. His
rebound with pressure to arm extension was approximately
6 inches, his muscle strength was normal but his reflexes
were absent in all extremities along with an absent vibra-
tion sense in both feet. He had normal temperature sensa-
tion in all extremities and a negative Babinski reflex
bilaterally. He demonstrated a mild fine tremor in the
right and left hand during finger to nose testing but no
resting tremor. His arm swing was normal with his walk-
ing but he had difficulty in tandem walking for greater
than 3 steps. He had a positive snout reflex for greater than
4 tabs, and a positive palmomental reflex with stroking the
right palm.
At present, he is on losartan 50 mg bid and propranolol
20 mg bid for his high blood pressure. He is on donepezil
10 mg qd and memantine 10 mg bid for his cognitive
dysfunction. He takes sertraline 50 mg qd although he
denies current depression. He also takes omeprazole
20 mg qd, aspirin 81 mg qd, simvastatin 40 mg qd and
iron heme polypeptide for his iron deficiency anemia. He
is on several eye drops including bimatoprost, brinzola-
mide, brimonidine tartrate and timolol maleate for his
glaucoma. His supplements include a multiple vitamin
without iron, Folic Acid 800 mcg qd, a probiotic, calcium
plus Vitamin D and B12 500 mcg per day along with an
additional omega-3 tablet.
Results
Results of IQ and memory testing indicated a rapid decline
during a 10 year follow-up (Table 1, Figure 1A–C). The
patient showed a 33 point difference in verbal comprehen-
sion, a 27 point difference in perceptual reasoning, a 17 point
difference in working memory, a 17 point difference in
processing speed and a 27 point difference in his full scale
IQ scoring over 10 years. In addition, his behavioral dyscon-
trol scale showed a 10 point difference and his mini mental
state examination demonstrated a 7 point difference. This
rapid and significant IQ loss is suggestive of progressive
neurodegenerative disorders, such as AD and FXTAS.
On his MRI, features of cerebral small vessel disease
(CSVD)17 including enlarged perivascular spaces, lacune,
and white matter hyperintensities (WMHs), are found as
early as age 74 before the onset of ataxia. His susceptibility-
weighted imaging (SWI) scans acquired at age 78 and
79 years show many cerebral microbleeds in the white
matter and all four lobes. Iron depositions are also shown
in the caudate nucleus, basal ganglia, substantia nigra, and
cerebellar dentate nucleus (Figure 2A–C). Volumetric ana-
lysis performed on high-resolution T1-weighted imaging
reveals that he has rapid atrophy (left hemisphere 1.24%/
year, right hemisphere 2.12%/year) most dramatically in the
hippocampus (left 3.35%/year, right 7.82%/year) and
amygdala (left 3.73%/year, right 7.73%/year) estimated
Table 1 The Results of IQ and Memory Testing Over Time
Time
of
Testing
Age of
Testing
WAIS
III/IV
VCI
WAIS
III/IV
PRI
WAIS
III/IV
WMI
WAIS
III/IV
PSI
WAIS
III/IV
FSIQ
BDS-2 MMSE WMS
III/IV
AMI
WMS
III/IV
VMI
WMS
III/IV
IMI
WMS
III/IV
DMI
2018 84 76 96 92 108 89 9/27 22 - - - -
2017 83 81 102 - - - 24/27 28 - - - -
2016 82 91 113 102 122 107 20/27 28 100 98 106 91
2014 80 102 105 102 124 109 25/27 29 95 100 97 96
2011 77 - - - - - 15/27 28 111 - - 114
2009 75 - - - - - 25/27 28 - - - -
2008 74 109 123 109 125 116 19/27 29 105 - - 102
Abbreviations: WAIS, Wechsler Adult Intelligence Test; WMS, Wechsler Memory Scale; VCI, Verbal Comprehension; PRI, Perceptual Reasoning; WMI, Working Memory;
PSI, Processing Speed; FSIQ, Full Scale IQ; AMI, Auditory Memory; VMI, Visual Memory; IMI, Immediate Memory; DMI, Delayed Memory; BDS2, Behavioral Dyscontrol
Scale2; MMSE, Mini-Mental State Examination.
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using mixed-effects modeling. Although he is right handed,
his right hemisphere experiences a faster rate of atrophy
than the left hemisphere. In contrast, some areas have rela-
tively preserved volumes and annual rate of atrophy includ-
ing the corpus callosum (0.87%/year), cerebellum white
matter (0.08%/year), and brainstem (1.03–1.31%/year)
compared with age-matched healthy controls (Table 2,
Figure 2D–L).18,19 The WMHs in the cerebral hemispheres
and periventricular regions show several confluent areas
bilaterally and significant age-related fast expansion
(21.7%/year). The white matter disease also involves the
right insula and the splenium of the corpus callosum, which
maintains normal thickness. He has a moderate degree of
ventricular dilation most substantially in the lateral ventri-
cles (13.7%/year for the lateral ventricles versus 4.14%/
year for the third ventricle and 0.21%/year for the fourth
ventricle) but he does not demonstrate the middle cerebellar
peduncle (MCP) sign. His PET scan of metabolism demon-
strated mildly decreased Fludeoxyglucose (FDG) uptake in
the bilateral parietotemporal lobes (right greater than left),
as well as mildly decreased FDG uptake in the bilateral
posterior cingulate gyri. This pattern of rapid atrophy of
the medial temporal lobe but relatively preserved cerebel-
lum and brainstem would be consistent with early progres-
sive neurodegenerative disorder, such as in AD.
Discussion
In this case study, we present the neuropsychological,
neurobehavioral and motor profile of an initially gifted
individual with a progressive cognitive decline and disin-
hibited behavior in addition to his motor symptoms. He
was diagnosed with FXTAS after developing tremor and
ataxia in addition to typical white matter disease on his
MRI. His IQ, memory and behavioral testing included in
this report showed a rapid loss of skills with age. His MRI
scans showed features of CSVD (i.e., enlarged perivascu-
lar spaces, lacune, WMHs and cerebral microbleeds), iron
depositions in the deep nuclei, and a rapid brain atrophy
most substantially in the medial temporal lobe but rela-
tively preserved in the cerebellum and brainstem.
Individuals with CGG repeats in the 60s are at lower
risk for FXTAS compared to those with higher CGG
repeat numbers in the premutation range. The age of
onset of FXTAS and the age of death correlate inversely
with the CGG repeat number.5 In a review of 40 brains of
premutation carriers the only 2 brains without FXTAS
inclusions were those with repeats in the 60s.20
Previous reports of rapid cognitive decline in those
with FXTAS demonstrated evidence of AD on neuro-
pathology in addition to the findings of FXTAS
inclusions.13 This patient showed a 26 point difference
between his current VCI and his VCI from 4 years ago
which is more typical of AD than FXTAS where verbal
abilities are relatively preserved.21 His processing speed
and full scale IQ also demonstrated a point difference of
16 and 25 respectively. This IQ loss is not unusual in
FXTAS neurocognitive disorder which can also involve
psychomotor slowing, retrieval and recall deficits, person-
ality changes and executive deficits.21 However, the pat-
tern of brain atrophy― substantially faster atrophy in the
hippocampus and amygdala relative to the rate of atrophy
A
B
C
Figure 1 (A–C) Changes in IQ and memory over 10 years follow-up.
Abbreviations: WAIS- Wechsler Adult Intelligence Test; VCI- Verbal Comprehension;
PRI- Perceptual Reasoning; WMI- Working Memory; PSI- Processing Speed; FSIQ- Full
Scale IQ; BDS-2 Behavioral Dyscontrol Scale-2; MMSE- Mini-Mental State Examination.
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Figure 2 Structural changes in the brain. (A–C) The SWI scan acquired at age 76 shows cerebral microbleeds in the white matter and all four lobes (circled in (A) and
arrows in (B)) as well as symmetric iron depositions in the caudate nuclei (arrowhead in (C)) and putamen (arrows in (C)). (D) The midsagittal slice of his T1 scan acquired
at age 84 shows the relatively reserved the corpus callosum, brainstem, and cerebellum. (E and F) Segmentation of the corpus callosum (cyan), lateral ventricles (steel blue),
third ventricle (brown), midbrain (blue), left amygdala (lime green), right amygdala (purple), left hippocampus (pink), and right hippocampus (salmon) on MRI scans acquired
at age 76 (E) and age 84 (F). (G-L) Volumetric changes in left (red) and right (turquoise) hemisphere (G), left and right hippocampus (H), left and right amygdala (I), white
matter hyperintensities (WMHs) (J), lateral ventricles (K), and cerebellar white matter (WM) (L).
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in the corpus callosum, cerebellum, and brainstem―is
consistent with AD; and his PET scan for AD demon-
strated significantly decreased activity in the parietal
regions bilaterally which is also consistent with AD. He
had an affectionate behavior to all people around him due
to his increasing frontal disinhibition.
There is variability in patients with FXTAS regarding
their symptoms. Although many patients with FXTAS
remain stable for years, others show rapidly progressive
symptoms.22 The rapid decline of these patients may be
related to another underlying pathology and in this case,
the additional etiology is likely AD. This patient had only
mild tremor and ataxia but the cognitive decline was
remarkable suggesting that in his later years the AD symp-
toms were the most significant of his problems.
Since he was at low risk to develop FXTAS because of
his low CGG repeat number, the onset and exacerbation of
his FXTAS is worthy of discussion. His symptoms of tremor
and balance problems started at an older age, greater than 10
years older than the mean age of onset at 62 years.4 His
symptoms also started after general surgery for his prostate
cancer and the anesthesia and the cancer itself could have
precipitated the onset.23 Although his tremor was minimal,
his ataxia was more problematic. He also developed anemia
and chronic renal failure and these problems can occasionally
be seen in those with FXTAS. Interestingly, likely due to
RNA toxicity, intranuclear inclusions were identified in the
bone marrow and in the kidneys of premutation carriers.6
Alternatively, or additionally, his anemia may have also been
related to anemia of chronic disease but the treatment of iron
infusions can exacerbate FXTAS and likely lead to cell death
(ferroptosis) because impaired iron transportation and iron
deposition have been demonstrated in the brain of those with
the premutation.9 In addition, endothelial cells with increased
iron load may subsequently drop off and facilitate
microbleeds.20,24 Indeed, many cerebral microbleeds in the
white matter and all four lobes were detected on his SWI
scans. The patient was also treated with aspirin, a blood
thinner which also predisposes to bleeding and likely pro-
gression of white matter disease. Lastly, as he aged into his
80s, the prevalence of AD symptom increases, and his
decline of cognition escalated. His PET scan demonstrated
dramatically decreased activation bilaterally in the parietal
lobes which is typical for AD. His MRI scans also showed
preferential degeneration of the medial temporal lobes and
relatively preserved cerebellum and brainstem also typical
for AD. The rapidity of his decline is more typical for AD
combined with FXTAS perhaps the molecular mechanisms
leading to neurodegeneration in both disorders are synergis-
tic. His frontal disinhibition is more typical of FXTAS
than AD. However, he is in the 40% of males affected by
FXTASwho do not show theMCP sign and this is likely why
his tremor is so mild. He also exercised daily, took antiox-
idants and treated his sleep apnea and his hypertension; the
latter 2 problems if left untreated can exacerbate FXTAS.25
Further research is needed to understand the anemia in
those with FXTAS especially since the treatment of iron
supplementation can exacerbate the CNS dysfunction in
Table 2 The Results of Mixed-Effects Modeling to Fit MRI Volumetric Data Using Age
Brain Areas Intercept (mL) β (mL) SE (mL) Rate (%/Year) P value
Left hemisphere 618.5 −7.64 1.163 −1.24 0.001
Right hemisphere 612.8 −12.98 0.987 −2.12 < 0.001
Corpus callosum 28.4 −0.25 0.034 −0.87 < 0.001
Cerebellar WM 19.7 0.02 0.183 0.08 0.94
Midbrain 9.76 −0.11 0.018 −1.1 0.001
Pons 16.89 −0.22 0.031 −1.31 < 0.001
Medulla 5.84 −0.06 0.005 −1.03 < 0.001
Left hippocampus 3.52 −0.12 0.018 −3.35 0.001
Right hippocampus 2.87 −0.22 0.022 −7.82 < 0.001
Left amygdala 1.69 −0.06 0.010 −3.73 0.001
Right amygdala 1.76 −0.14 0.013 −7.73 < 0.001
Lateral ventricles 39.3 5.36 0.578 13.65 < 0.001
Third ventricle 3.00 0.12 0.021 4.14 0.001
Fourth ventricle 2.85 0.01 0.020 0.21 0.76
Whole brain WMHs 13.5 2.93 0.392 21.71 < 0.001
Notes: The annual rate of change is calculated based on the intercept, the fitted value for the 2010 visit.
Abbreviations: WM, white matter; WMHs, white matter hyperintensities.
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FXTAS. Iron transportation in the choroid plexus is dys-
regulated in FXTAS and iron is deposited in the CNS.9,26
His SWI Scans acquired at age 78 and 79 years showed
iron depositions in the deep nuclei, including the caudate
nuclei, basal ganglia, substantia nigra, and cerebellar den-
tate nuclei. Perhaps chelation to extract iron from the CNS
is needed for those with FXTAS showing iron depositions
in the deep nuclei but such therapy has not been studied in
FXTAS.
In summary, there is a high degree of variability in
the clinical presentation of FXTAS. Additional neurode-
generative diseases can be present and likely exacerbate
the progression of the disease, as previously reported.1
Perhaps one disorder may precipitate the onset of
another disease because of oxidative stress or mitochon-
drial dysfunction and further studies are needed to
understand synergistic effects of two or more disorders.
When significant neurocognitive disorder combined with
medial temporal lobe atrophy emerges in those with
FXTAS, evaluation for AD and other neurocognitive
disorders that can be overlapping with FXTAS should
be considered. In the future, neuropathological studies
will help us understand the progression of this patient’s
symptoms.
Limitations and Further Research
Although the cognitive test and neuroimaging data are sug-
gestive of AD, amyloid imaging is lacking, which can be
useful for ruling out AD if amyloid plaques are absent. This
case report shows the need for further research to explain the
effects of two or more neurodegenerative disorders when
they co-occur in a patient.
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